Comparison of efficacy and safety of second- and third-generation TKIs for non-small-cell lung cancer with uncommon EGFR mutations.
Yue HaoManyi XuJianan JinJinfei SiChun-Wei XuZhengbo SongPublished in: Cancer medicine (2023)
The efficacy of second- and third-generation TKIs for NSCLC with uncommon EGFR mutations does not differ, and so can be used to treat NSCLC patients with these mutations.